ESMO: Pivotal Keytruda Combination Hits And Misses

 
• By Ayisha Sharma

Merck & Co’s mega-blockbuster checkpoint inhibitor Keytruda hit new clinical highs and lows at ESMO as the major ramps up efforts to expand the drug’s label by exploring novel combinations and cancer settings.  

Arrow hitting the bullseye on an archery board
Keytruda Combinations Hit The Mark In Bladder Cancer And Lung Cancer • Source: Shutterstock

More from Clinical Trials

More from R&D